var data={"title":"Polyethylene glycol electrolyte solution and bisacodyl: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Polyethylene glycol electrolyte solution and bisacodyl: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6799?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=polyethylene-glycol-electrolyte-solution-and-bisacodyl-patient-drug-information\" class=\"drug drug_patient\">see &quot;Polyethylene glycol electrolyte solution and bisacodyl: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211176\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>GaviLyte-H and Bisacodyl;</li>\n      <li>HalfLytely and Bisacodyl [DSC];</li>\n      <li>PEG-Prep and Bisacodyl</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49728503\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Bi-Peglyte</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211189\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Laxative, Bowel Evacuant;</li>\n      <li>\n        Laxative, Stimulant</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211178\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Bowel cleansing: </b>Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bisacodyl: 5 mg as a single dose. After bowel movement or 6 hours (whichever occurs first), initiate polyethylene glycol-electrolyte solution </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Polyethylene glycol-electrolyte solution: 8 ounces every 10 minutes until 2 L are consumed</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211179\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22448431\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in manufacturer&rsquo;s labeling. Use with caution due to risks of fluid and electrolyte abnormalities.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22448432\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211162\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kit [each kit contains]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GaviLyte-H and Bisacodyl:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Powder for solution, oral (GaviLyte-H): PEG 3350 210 g, sodium bicarbonate 2.86 g, sodium chloride 5.6 g, potassium chloride 0.74 g (2000 mL) [contains 3 flavor packs: cherry, lemon, orange]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Tablet, delayed release, oral (Bisacodyl): 5 mg (1s)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">HalfLytely and Bisacodyl [DSC]:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Powder for solution, oral (HalfLytely): PEG 3350 210 g, sodium bicarbonate 2.86 g, sodium chloride 5.6 g, potassium chloride 0.74 g (2000 mL) [contains 4 flavor packs: cherry, lemon-lime, orange, pineapple]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Tablet, delayed release, oral (Bisacodyl): 5 mg (1s)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">PEG-Prep and Bisacodyl:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Powder for solution, oral (PEG-Prep): PEG 3350 210 g, sodium bicarbonate 2.86 g, sodium chloride 5.6 g, potassium chloride 0.74 g (2000 mL) [contains 3 flavor packs: cherry, lemon, orange]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Tablet, delayed release, oral (Bisacodyl): 5 mg (1s)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211149\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49744260\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kit [each kit contains]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bi-Peglyte Bowel Prep Kit:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">PEG 3350 59.55 g, sodium bicarbonate 1.69 g, sodium chloride 1.46 g, sodium sulfate 5.74 g, potassium chloride 0.76 g (1000 mL ) [contains 2 sachets: fruit flavor] [contains saccharin sodium]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Tablet, delayed release, oral (Bisacodyl): 5 mg (3s)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10972919\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM220644.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV68uZt0IO6WNLdLcxWu19XMlQ==&amp;TOPIC_ID=10194\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM220644.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211165\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer bisacodyl tablet with water; do not chew or crush tablet. Do not take antacids within 1 hour of taking bisacodyl. Rapidly drinking the polyethylene glycol-electrolyte solution is preferred to drinking small amount continuously. If severe bloating, distention, or abdominal pain occurs, administration should be slowed or temporarily discontinued until symptoms resolve. Oral medications should not be administered within 1 hour of start of therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211164\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Bowel cleansing prior to colonoscopy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211153\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Malaise (57%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Gastrointestinal fullness (40%), abdominal cramps (38%), nausea (34%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%: Gastrointestinal: Vomiting (10%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing and/or case reports: Anaphylaxis, aspiration, asystole, dermatitis, dizziness, dyspnea, esophageal perforation, hypersensitivity reaction, ischemic colitis, Mallory-Weiss syndrome, pulmonary edema, rhinorrhea, seizure (using the 4 L preparation), syncope, urticaria </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211168\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-4em;margin-left:4em;\">Gastrointestinal obstruction; bowel perforation; toxic colitis; toxic megacolon; gastric retention; ileus </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bi-Peglyte [Canadian product]: Hypersensitivity to bisacodyl, polyethylene glycol or any component of the formulation; ileus; gastric retention; GI obstruction; bowel perforation; toxic colitis; toxic megacolon; acute surgical abdomen; appendicitis; rectal bleeding; gastroenteritis; diverticulitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211151\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Concerns related to adverse effects:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Arrhythmias: Serious arrhythmias have been reported (rarely) with the use of ionic osmotic laxative products. Use with caution in patients who may be at risk of cardiac arrhythmias (eg, patients with a history of prolonged QT, uncontrolled arrhythmias, recent MI, unstable angina, CHF, or cardiomyopathy). Consider pre-dose and post-colonoscopy ECGs in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Fluid/electrolyte loss: Fluid and electrolyte disturbances can lead to arrhythmias, seizures, and renal impairment. Advise patients to maintain adequate hydration before, during, and after treatment. If patient becomes dehydrated or experiences significant vomiting after treatment, consider post-colonoscopy lab tests (electrolytes, creatinine, and BUN).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Ischemic colitis: Cases of ischemic colitis have been reported; development of severe abdominal pain or rectal bleeding should prompt further evaluation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Seizures: Generalized tonic-clonic seizures have occurred in patients with no prior history of seizures when using the large volume (4 L) preparation.  Seizures resolved with the correction of fluid and electrolyte abnormalities.  Use caution in patients taking medications which increase the risk for electrolyte abnormalities (eg, diuretics) and/or patients with pre-existing electrolyte abnormalities.  Evaluation of electrolytes pre- and post-colonoscopy is warranted in this population.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Impaired gag reflex: Observe unconscious or semiconscious patients with impaired gag reflex or those who are otherwise prone to regurgitation or aspiration during administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment and/or  in patients taking medications that may adversely affect renal function (eg, diuretics, NSAIDs, ACE inhibitors). Patients with impaired renal function who develop severe vomiting should be closely monitored including measurement of electrolytes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Ulcerative colitis: Use with caution in patients with severe ulcerative colitis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Evaluate patients with symptoms of bowel obstruction or perforation prior to use. Correct electrolyte abnormalities in patients prior to use. No additional ingredients or flavors (other than the flavor packs provided) should be added to the polyethylene glycol-electrolyte solution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299901\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211155\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10194&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May diminish the therapeutic effect of Bisacodyl. Antacids may cause the delayed-release bisacodyl tablets to release drug prior to reaching the large intestine.  Gastric irritation and/or cramps may occur.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211157\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211170\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Reproductive studies have not been conducted with this combination.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211171\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Drink only clear liquids the day of and during the bowel preparation; after consuming the solution, avoid drinking large quantities of clear liquids until colonoscopy. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211160\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Bowel movements; electrolytes, renal function</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211150\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Bisacodyl acts on the colonic mucosa to increase peristalsis throughout the large intestine. Polyethylene glycol-electrolyte solution induces catharsis through strong electrolyte and osmotic effects.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211167\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3422275\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (GaviLyte-H Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5-210 mg-g (1): $85.10</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (PEG-Prep Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5-210 mg-g (1): $94.67</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bi-Peglyte (polyethylene glycol 3350 and electrolytes and bisacodyl) [prescribing information]. Pendopharm, Division of Pharmascience Inc; October 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DiPalma JA, McGowan J, and Cleveland M, &ldquo;Clinical Trial: An Efficacy Evaluation of Reduced Bisacodyl Given as Part of a Polyethylene Glycol Electrolyte Solution Preparation Prior to Colonoscopy,&rdquo; <i>Aliment Pharmacol Ther</i>, 2007, 26(8):113-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-electrolyte-solution-and-bisacodyl-drug-information/abstract-text/17894653/pubmed\" target=\"_blank\" id=\"17894653\">17894653</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DiPalma JA, Wolff BG, Meagher A, et al, &ldquo;Comparison of Reduced Volume Versus Four Liters Sulfate-Free Electrolyte Lavage Solutions for Colonoscopy Colon Cleansing,&rdquo; <i>Am J Gastroenterol</i>, 2003, 98(10):2187-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-electrolyte-solution-and-bisacodyl-drug-information/abstract-text/14572566/pubmed\" target=\"_blank\" id=\"14572566\">14572566</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    GaviLyte-H and Bisacodyl (polyethylene glycol-electrolyte solution and bisacodyl) [prescribing information]. Somerset, NJ: Novel Laboratories.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10194 Version 67.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F211176\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F49728503\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F211189\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F211178\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F211179\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22448431\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22448432\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F211162\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F211149\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F49744260\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F10972919\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F211165\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F211164\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F211153\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F211168\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F211151\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299901\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F211155\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F211157\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F211170\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F211171\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F211160\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F211150\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F211167\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F3422275\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10194|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=polyethylene-glycol-electrolyte-solution-and-bisacodyl-patient-drug-information\" class=\"drug drug_patient\">Polyethylene glycol electrolyte solution and bisacodyl: Patient drug information</a></li></ul></div></div>","javascript":null}